Congrats to Life Science Cares Boston board member John Maraganore on this new endeavor! #LSCImpact
Exclusive: John Maraganore, the former CEO of Alnylam Pharmaceuticals Therapeutics turned biotech elder statesman and venture capitalist, is launching a new startup that he hopes can expand upon his previous company’s success. City Therapeutics wants to deliver treatments to hard-to-reach tissues by using new delivery vehicles and smaller versions of RNA molecules called cleavage inducing tiny RNAs, or “cityRNAs” — hence, the startup’s name. “Alnylam will be, in my view, the indisputable leader in this space for many, many years to come. I think Alnylam will become a $100 billion company up there with Vertex and Regeneron and Gilead and Amgen,” Maraganore said. “I’m a big believer in where Alnylam is going, but RNAi is even bigger than that, and there’s a need for new pioneers in the space. City Therapeutics is my next-generation RNAi play.” How far do you think the RNAi field can go? And what do you think of City Therapeutics' strategy? Comment below! #biotech #startups #RNAi #genesilencing #genetherapy #fundraising #SeriesA #venturecapital STAT